Recently, Adekambi et al. found that host blood-based biomarkers including CD38, HLA-DR, and Ki-67 on M. tb-specific CD4+ T cells could help discriminate between active TB and LTBI and could be a biomarker for monitoring treatment response and cure [34]. The gene discussed is CD38; the disease is tuberculosis.